Mangoceuticals, INC 8-K filings

Mangoceuticals, Inc. announced a business combination agreement with Nuclea Energy Inc. to advance Nuclea's Morpheus microreactor technology.

Mangoceuticals, Inc. has entered into a subscription agreement with an accredited investor for the purchase of 850,000 shares of restricted common stock, raising $272,000.

Mangoceuticals, Inc. repriced CEO Jacob Cohen's stock options to $0.45 per share and filed a lawsuit seeking over $73 million against its former technology consultant, Clarity Ventures, Inc.

Mangoceuticals announced new data for its antiviral compound MGX-0024, showing zero respiratory-related mortality in large-scale poultry field trials and prophylactic benefits against H5N1.

Mangoceuticals reports significant initial success for its new $99/month injectable Testosterone Replacement Therapy program, boasting 336% month-over-month sales growth and a 54% reduction in customer acquisition costs.

Mangoceuticals, Inc. received a Nasdaq deficiency notice for failing to maintain a minimum bid price of $1.00 per share.

Mangoceuticals, Inc. announced a $2.5 million capital raise through a registered direct offering of common stock and pre-funded warrants, alongside a concurrent private placement of common stock purchase warrants.

Mangoceuticals, through its new subsidiary Mango DAT, partners with Cube Group to launch an up to $100 million Solana-focused digital asset treasury strategy.

Mangoceuticals, Inc. has entered into a $75,000 promissory note with The Tiger Cub Trust, controlled by its CEO and Chairman, Jacob D. Cohen, bearing an 18% annual interest rate.

Mangoceuticals clarifies its new weight-management programs offer access to FDA-approved branded GLP-1 medications like Zepbound and Wegovy through a third-party provider, not direct contracts with Eli Lilly or Novo Nordisk.

Mangoceuticals launches MangoRx Direct and PeachesRx Direct, partnering with Eli Lilly and Novo Nordisk to provide affordable access to Zepbound and Wegovy for obesity management.

Mangoceuticals, Inc. announced a new five-year office lease, the departure of its Chief Operating Officer with a severance package, and recent conversions of Series B Preferred Stock into common shares.

Mangoceuticals, Inc. announced significant equity compensation for its CEO and other key executives and directors, including 2 million stock options for CEO Jacob D. Cohen.

Mangoceuticals, Inc. announced it raised $1.1 million through a private placement of 709,677 restricted common shares to five accredited investors at $1.55 per share.

Mangoceuticals, Inc. rescinded its exclusive distribution agreement for Diabetinol with Navy Wharf, leading to the cancellation of 1,000,000 shares, and also raised $297,000 through a warrant exercise.

Mangoceuticals, Inc. announced a series of financing activities, including the amendment of a convertible promissory note with its CEO's trust, the issuance of new warrants, the conversion of a significant debt, and further drawdowns from its existing equity line of credit.

The company has designated 1,000,000 shares of 6% Series B Convertible Cumulative Preferred Stock, establishing specific dividend, liquidation, conversion, and redemption rights.

Mangoceuticals, Inc. announced the resignation of Antonios 'Tony' Isaac from his roles as President and member of the Board of Directors, effective June 30, 2025.

Mangoceuticals, Inc. has filed an 8-K detailing multiple equity transactions, including warrant exercises, preferred stock conversions, and a sale of common stock under its existing Equity Line of Credit, resulting in the issuance of 498,314 new shares and raising approximately $343,190 in cash.

Mangoceuticals, Inc. announced a series of strategic financial and operational agreements, including a unit offering that raised $116,249, an amendment to a $500,000 convertible promissory note, and a new digital marketing services agreement.

Mangoceuticals, Inc. announced the mutual rescission of three material agreements with ArcStone Securities, Smokeless Technology, and Strategem Solutions, effectively unwinding recent share-based transactions and strategic initiatives.

Mangoceuticals, Inc. entered into a $100,000 loan agreement with The Tiger Cub Trust, converted preferred stock into common stock, and settled a lawsuit by issuing restricted common stock.

Mangoceuticals expands into the oral pouch market by acquiring Smokeless Technology Corp.'s IP and appoints Tim Corkum, a former Philip Morris executive, to head the new pouch division.

Mangoceuticals, Inc. announces the completion of a $100,000 Series B Preferred Stock sale and a $500,000 promissory note to bolster its financial position.

Mangoceuticals, Inc. granted fully-vested shares of common stock to its officers and directors as a discretionary bonus for services rendered during 2025.

Mangoceuticals reports the conversion of Series B Convertible Preferred Stock and debt held by MAAB Global Ltd. into common stock.

Mangoceuticals reports the conversion of Series B Convertible Preferred Stock into common stock on March 28, 2025.

Mangoceuticals, Inc. reports the conversion of Series B Convertible Preferred Stock into common stock by several holders, impacting the company's equity structure.

Mangoceuticals secures exclusive rights to market and sell Diabetinol, a plant-based nutraceutical for managing blood glucose, in the U.S. and Canada, expanding into the $33 billion diabetes market.

Mangoceuticals modifies the conversion price and other terms of its Series B Convertible Preferred Stock and approves a second amendment to its 2022 Equity Incentive Plan.